Clinical characteristics and therapeutic effect of TP53 variant in patients with acute leukemia.
10.3760/cma.j.cn511374-20200414-00262
- Author:
Ruihua MI
1
;
Zhen GUO
;
Wen LIU
;
Jieying HU
;
Ruihua FAN
;
Lin CHEN
;
Jia LIU
;
Xudong WEI
Author Information
1. Department of Hematopathy, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450008, China. weixudong63 @126.com.
- Publication Type:Journal Article
- MeSH:
Acute Disease;
Humans;
Leukemia, Myeloid, Acute/genetics*;
Middle Aged;
Mutation;
Retrospective Studies;
Tumor Suppressor Protein p53/genetics*
- From:
Chinese Journal of Medical Genetics
2021;38(10):955-960
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the clinical characteristics and prognostic values of TP53 gene variant in patients with acute leukemia(AL).
METHODS:The clinical data of 44 newly diagnosed AL patients with TP53 variant detected by next generation sequencing (NGS) were analyzed retrospectively. Targeted sequencing technique containing 108 leukemia-related genes was used for variant analysis, and conventional R-banding technique was used for karyotype analysis. The clinical features, cytogenetics, gene variant, curative effect and survival of AL patients with TP53 gene variant were analyzed.
RESULTS:The median age of AML patients with TP53 gene variant (46 years) was higher than that of ALL patients (17.5 years), and the median number of bone marrow blasts (40.5%) was lower than the latter (89.2%), the differences were statistically significant (P< 0.01). A total of 28 cases of abnormal karyotype were detected, of which 25 cases were complex karyotype, 16 cases were monomeric karyotype, 14 cases had -17/17p-. The detection rates of TP53 in complex karyotype, monomeric karyotype and -17/17p- were 59.5%, 38.1% and 33.3%, respectively. Subgroup analysis showed that the detection rate of TP53 gene abnormalities in AML and ALL complex karyotypes was 73.1% and 40% respectively, the difference was statistically significant. A total of 41 TP53 gene variant types were found, and the median variant frequency was 43.58%. 75.6% variant was located in the DNA binding domain. The concomitant variant genes were mainly TET2 and IKZF1. Among 18 AML and 17 ALL patients who could be evaluated the curative effect, the CR rate of one course of treatment was 22.2% and 94.12% respectively, and the difference was statistically significant. The median RFS of 4 cases of AML with CR and 16 cases of ALL with CR were 174 and 246 days respectively, the difference was statistically insignificant. The median OS of AML and ALL was 20 and 375 days respectively, the difference was statistically significant.
CONCLUSION:The TP53 gene variant is associated with the complex karyotype of AML, but has no significant effect on ALL. The variant site of TP53 gene was mainly distributed in the DNA binding domain. The remission rate of AML with TP53 gene variant was lower than that of ALL. The prognosis of AL patients with TP53 gene variant is poor, so allogeneic hematopoietic stem cell transplantation should be performed as soon as possible to prolong the survival of the patients.
